Stifel Maintains Hold on Allogene Therapeutics, Raises Price Target to $4.6
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett maintains a Hold rating on Allogene Therapeutics (NASDAQ:ALLO) and raises the price target from $4.4 to $4.6.
May 14, 2024 | 10:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst maintains a Hold rating on Allogene Therapeutics but raises the price target from $4.4 to $4.6, indicating a slight positive adjustment in the stock's valuation.
The increase in price target by Stifel suggests a modestly improved outlook for Allogene Therapeutics, potentially leading to a positive short-term impact on the stock. The Hold rating indicates stability, while the price target adjustment reflects a slight optimism.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100